Morphine is an analgesic alkaloid used to relieve severe pain, and irreversible binding of morphine to specific unknown proteins has been previously observed. In the brain, changes in the expression of energy metabolism enzymes contribute to behavioral abnormalities during chronic morphine treatment. Creatine kinase B (CK-B) is a key enzyme involved in brain energy metabolism. CK-B also corresponds to the imidazolinebinding protein I 2 which binds dopamine (a precursor of morphine biosynthesis) irreversibly. Using biochemical approaches, we show that recombinant mouse CK-B possesses a µM affinity for morphine and binds to morphine in vitro. The complex formed by CK-B and morphine is resistant to detergents, reducing agents, heat treatment and SDS-polyacrylamide gel electrophoresis (SDS-PAGE). CK-B-derived peptides CK-B 1-75 and CK-B 184-258 were identified as two specific morphine binding-peptides. In vitro, morphine (1-100 µM) significantly reduces recombinant CK-B enzymatic activity. Accordingly, in vivo morphine administration (7.5 mg/kg, i.p.) to mice significantly decreased brain extract CK-B activity compared to saline-treated animals. Together, these results show that morphine strongly binds CK-B and inhibits its activity in vitro and in vivo.
demonstrated that the phosphatidylethanolamine-binding protein (PEBP; Goumon et al., 2004) binds to morphine-6-glucuronide (M6G) and morphine-3-glucuronide (M3G) with an affinity equal to that of its reference ligand, phosphatidylethanolamine, but has no affinity for morphine (Atmanene et al., 2009) . In addition to these low affinity bindingproteins, covalent binding of morphine to proteins has been proposed to result in irreversible binding to insoluble tissue components after administration Mullis et al., 1979; Nagamatsu et al., 1983) .
The implication of the imidazoline system, and particularly the I 2 -binding site (I2B; Li, 2017) , in the modulation of morphine-induced analgesia and morphine analgesic tolerance has been documented (Gentili et al., 2006; Caprioli et al., 2015) . Interestingly, creatine kinase B (CK-B) represents the main I2B site for imidazoline and its derivatives (clonidine, guanfacine; Kimura et al., 2009; Li, 2017) . Molecular modeling using the crystal structure of chicken CK-B and the irreversible ligand BU990006-binding site has indicated the importance of Thr 71 , Val 72 , Val 75 , Leu 201 , Leu 202 , Cys 283 and Ser 285 in this interaction (Kimura et al., 2009 ). Dopamine, a morphine precursor in plants and mammals (Laux-Biehlmann et al., 2013) , has been shown to covalently bind to CK-B (Van Laar et al., 2009) . CK-B also forms highly stable complexes with ankyrin repeat and SOCS box protein 9 (ASB9; Balasubramaniam et al., 2015) .
CK-B is a 42 kDa protein expressed in neurons, oligodendrocytes and astrocytes of the central nervous system (CNS; Manos and Bryan, 1993) . Different CK isoenzymes exist in the cytoplasm as dimers or multimers in specific cells: CK-BB in the brain, CK-MM in muscles and CK-MB in the heart (Wyss and Kaddurah-Daouk, 2000) . CK catalyzes the reversible phosphorylation of creatine by ATP to produce phosphocreatine and ADP. Mitochondrial isoforms of CK form phosphocreatine from ATP, whereas cytoplasmic CK isoenzymes form ATP from phosphocreatine.
In the present study, we have investigated whether CK-B might represent a morphine-binding protein. Recombinant mouse CK-B (rCK-B) and mouse CK-B-derived synthetic peptides, together with biochemistry approaches, were used to characterize the affinity of potential morphine-binding sites. To assess the functional significance of CK-B/morphine interactions, the impact of morphine on rCK-B activity was studied in vitro and in vivo.
MATERIALS AND METHODS

Experimental Design
Our animal study is reported in accordance with the ARRIVE Guidelines for reporting experiments involving animals (McGrath et al., 2010) . Experiments were carried out in a randomized and blind manner, and statistical analyses were done prior to revealing treatment groups. At least three technical replicates were used for in vitro experiments. Mice were assigned an identity number and assigned to groups randomly so that the experimenter was blind to treatment.
Drugs
Morphine base was purchased from Euromedex (Souffelweyersheim, France). A stock solution of 35 mM morphine was prepared by dissolving morphine in H 2 O after adding an equimolar concentration of HCl. Codeine monohydrate, morphine-3-β-D-glucuronide and morphine-6-β-D-glucuronide dihydrate powders were purchased from Sigma-Aldrich (Lyon, France) and dissolved in H 2 O to prepare stock solutions. Working concentrations for in vitro and in vivo experiments were prepared from the stock on the day of experiment. When necessary, the pH of the working solutions was adjusted to 7.4 with NaOH before use.
Animals
All procedures were performed in accordance with European directives (86/609/EEC) and were approved by the regional ethics committee and the French Ministry of Agriculture (license No. 00456.02 to YG). Experiments were performed with C57BL/6 mice (45 day-old adult male, 24 ± 3 g; Charles River, L'Arbresle, France). Animals were given food and water ad libitum, and maintained in a 12 h light-dark cycle at a room temperature of 22 • C ± 2 • C. Cage bedding was from Anibed (Pontvallain, France; reference AB3) and food from SAFE (Augy, France; reference A04). Mice were kept group-housed at five per cage (Type II cage, 370 cm 2 , height 14 cm).
Drug Injections
Mice were weighed and then i.p. injected (light phase at 10 AM) with a single dose of 7.5 mg/kg morphine or an equivalent volume of saline (NaCl 0.9% in H 2 O). The volume of injection was 240 ± 30 µL for mice weighing 24 ± 3 g. After 90 min, mice were anesthetized with a solution of ketamine and xylazine (17 mg/mL ketamine and 2.5 mg/mL xylazine, 4 mL/kg i.p.; Centravet, Taden, France). After 5 min, adequate anesthesia was ensured by pinching the hind paws and observing no reflex response. Animals were then euthanized by decapitation. Brains were then collected and frozen at −80 • C.
MR205953, Origene, Herford, Germany) was cloned into the vector pET15b (CIGEx, CEA, Fontenay aux Roses, France). The N-terminal hexahistidine-tagged fusion protein was expressed in Escherichia coli BL21 (DE3). Cells were grown in LB medium (Euromedex) at 37 • C until an A 600 of 0.4 and subsequently induced for 3 h at 37 • C with 0.1 mM isopropyl 1-thio-Dgalactopyranoside (Euromedex). Harvested bacterial pellets were resuspended in buffer containing isopropyl thio-β-d-galactoside (IPTG; Euromedex). The cell pellets were resuspended in binding buffer (10 mM Tris-HCl, 300 mM NaCl, 10% glycerol, 2 mM CHAPS and 10 mM imidazole, pH 8.0; Euromedex), lysed by sonication on ice (8 × 30 s, 90 W) and then clarified by centrifugation (20,000× g, 50 min, 4 • C). The cleared supernatant was loaded on a nickel-Hitrap column (GE Healthcare; Aulnay Sous Bois, France). The protein was eluted using 50 and 250 mM imidazole (10 mM Tris-HCl, 300 mM NaCl, pH 8.0; Euromedex). The protein was then dialyzed 12 h at 4 • C against a buffer containing 10 mM Tris, and 150 mM NaCl (pH 8). The purity and homogeneity of the protein were assessed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE; see below).
Enzyme-Linked ImmunoSorbent Assay (ELISA)
Enzyme-linked immunosorbent assays (ELISAs) were performed to determine the affinity and specificity of the binding of mouse rCK-B and its derived peptides to opiate alkaloids. 96-well plates (NUNC, Roskilde, Denmark) were coated for 1 h at 37 • C with 100 µl of a solution of CK-B-derived peptides or rCK-B (10 µg/ml) in carbonate-bicarbonate buffer (15 mM Na 2 CO 3 , 35 mM NaHCO 3 , pH 9.6). After three washes with 100 mM phosphate buffer pH 7.4 (PT buffer; 5 min), the wells were incubated for 30 min with 200 µl of bovine serum albumin (BSA) diluted in PT buffer (5%, w/v; PT-BSA buffer) to saturate non-specific sites. After saturation, wells were incubated for 1 h with 100 µl of morphine, M6G, M3G or codeine, diluted in H 2 O at increasing concentrations. The plate was then washed three times with PT buffer, and 100 µl of the mouse primary anti-morphine antibody (which detects morphine, codeine, M3G and M6G according to the manufacturer's antibody datasheet) diluted in PT-BSA buffer (1:2,000, v/v; 3A6, ref AMM00033; Aviva System Biology, San Diego, CA, USA) were added. After three more washes with PT buffer, 100 µl of the secondary antibody in PT-BSA buffer (HRP-conjugated donkey anti-mouse IgG, P.A.R.I.S. CliniSciences, Nanterre, France; 1:500, v/v) were added and incubated for 30 min at room temperature. After two washes with PT buffer, followed by two washes with a pH 7.5 phosphate-citrate-0.05% Tween 20 buffer (10 min), revelation was performed with 200 µl of a 1-Step Ultra TMB substrate solution (3,3 ,5,5 tetramethylbenzidine, Thermo Fischer Scientific). After 15 min of incubation at RT, the reaction was stopped by the addition of 50 µl of 2N hydrochloric acid. Optical density was determined at 450 nm with a Multiskan EX plate reader (Thermo Life Sciences, Cergy Pontoise, France). Each ELISA points was tested in triplicate in three independent experiments. All samples with a triplicate CV > 10% were retested to obtain a CV below or equal to 10%.
Association Assays
Association assays were performed with 0.5 µg of the mouse rCK-B in the presence of 1 or 5 µg of morphine, in a final volume of 10 µl incubated during 15 min at 37 • C. Samples were diluted 1:2 with the gel-loading buffer (see below).
Gel Electrophoresis
Proteins were separated on SDS-PAGE gradient gels (4%-12% acrylamide; Novex, MES running buffer). Samples were suspended in 20 µl of loading buffer containing 60 mM Tris HCl pH 6.8, 2% SDS (w/v), 4 M urea, 5% glycerol (v/v), 5 mM EDTA, 1% β-mercaptoethanol (v/v) and 0.05% bromophenol blue (w/v) and subjected to heat treatment (100 • C, 5 min). Gels were run in duplicate. One gel was silver-stained, and the other one was used for Western Blot analysis (see below).
Silver Staining
Silver staining was done according to the manufacturer's (Proteabio Europe, Langlade, France) instructions. Silver-stained gels and Western Blot analysis with an anti-CK antibody were used to assess the stability of CK after heat treatment. No difference in silver-stained band intensity or immunoreactivity was noticed in any experiment.
Western Blot
After electrophoretic separation, the gel was electrotransferred onto a polyvinyldifluorene (PVDF) membrane (Bio-Rad). PVDF membranes were treated for 30 min with a saturation solution containing PBS, 5% BSA (w/v) and 0.05% Tween 20 (v/v). Then, PVDF membranes were incubated with the 3A6 mouse monoclonal anti-morphine primary antibody for 1 h at room temperature (1:1,000). The mouse monoclonal 3A6 anti-morphine antibodies (ref AMM00033; Aviva System Biology) were raised against a ((5 alpha 6 alpha) 7 8 didehydro-4 5 epoxy-17methylmorphinan-3 5diol)-BSA conjugate. Binding of the primary antibody was detected using HRP-conjugated donkey anti-mouse antiserum (P.A.R.I.S.; 1:50,000 in PBS, 5% of BSA (w/v), 0.05% Tween 20 (v/v)). Luminata FORTE TM (Millipore, France) was used as the substrate. Non-specific binding of the secondary antibody was ruled out by omitting the primary antibody: non-specific labeling was absent with the secondary antibody alone (data not shown). 
Peptide Synthesis
Circular Dichroism
Circular dichroism spectra were recorded from 260 nm to 190 nm using a J-810 spectropolarimeter (Jasco, Tokyo, Japan). Spectral resolution and data pitch were adjusted to 1 nm while the scanning speed was set up at 50 nm/min. Samples containing 0.2 mg/mL of CK-B 1-75 in H 2 O (pH 6) and CK-B 184-258 (in 2.5 mM of NaOH, pH 7) were transferred into a quartz cuvette of 1 mm path length and maintained at the temperature of 23 • C. The absence of aggregates was confirmed by a Dynamic Light Scattering analysis (DLS, Zetasizer NanoS; Malvern Panalytical, Malvern, UK). The secondary structures of the peptides were calculated from the spectra using a least squares fit procedure implemented in the DicroProt analysis software (Deléage and Geourjon, 1993) .
CK Activity Assay
We used a commercial creatine kinase activity assay kit (MAK116, Sigma-Aldrich) to measure the potential impact of morphine binding on CK-B enzymatic activity. The protocol followed the manufacturer's instructions at room temperature. Briefly, 1 µg of rCK-B or 75 µg of brain extract were added per well (96-well plates, NUNC) with increasing concentrations of morphine (0, 0.01, 0.1, 1, 10, 25, 50, 100 µM final). The reconstituted reagent (made of assay buffer, enzyme mix and substrate solution) was then added to start the reaction. Fluorescence was recorded using a Mithras LB940 fluorescence plate reader (Berthold, Bad Wildbad, Germany), with excitation and emission filters of 350 nm and 460 nm, respectively. Four replicates were used for each data point.
Statistics
Data were analyzed using Graphpad Prism Software 7.0. Non-parametric statistical tests were used due to low sample size and the non-Gaussian distribution of some groups. For in vitro rCK-B assays, data were expressed as percentage of the control (no morphine condition) to account for variability across replicates done on separate days. Statistical differences were tested with the Kruskal-Wallis test and Dunn's multiple comparisons as post hoc. Brain extract assays were analyzed using the Mann-Whitney U test. Differences between groups were considered statistically significant at p < 0.05.
RESULTS
Characterization of the CK-B Affinity for Morphine
The binding of mouse rCK-B, produced in E. coli to increasing concentrations (1.56 µM to 400 µM) of morphine, codeine, M3G or M6G was tested by ELISA. The results show that mouse rCK-B binds morphine ( Figure 1A ) with a calculated Kd of 10.8 µM. Our results further revealed that M3G, M6G and codeine only weakly bind to rCK-B (Kd > 100 µM) compared to morphine. As a non-specific binding control, a series of wells were coated with BSA instead of rCK-B and incubated with increasing concentrations of morphine, M3G or M6G. No binding of morphine, M3G or M6G to BSA was observed ( Figure 1A, control) .
Together, these results indicate that rCK-B binds morphine with a micromolar range affinity.
Characterization of a Morphine-rCK-B Complex Resistant to SDS-PAGE
Mouse rCK-B (0.5 µg) was incubated 15 min in the presence of 1 or 5 µg of morphine. Samples were resuspended in loading buffer containing both SDS and urea. A heating step (100 • C; 5 min) was performed before polyacrylamide gel electrophoresis (PAGE).
Western Blot analysis using anti-morphine antibody showed that the mouse rCK-B alone is not labeled by the anti-morphine antibody ( Figure 1B, left panel) . Morphine immunolabeling was observed at 42 kDa (CK-B monomers) and 84 kDa (CK-B dimers) only when CK-B was incubated with 1 and 5 µg of morphine. As a control, an identical gel was run in parallel and silver-stained ( Figure 1B, right  panel) . This control shows the presence of two bands at 42 kDa and 84 kDa in each condition. These two bands correspond to the monomers and dimers of mouse rCK-B, respectively.
These results indicate that morphine-mouse rCK-B complexes are resistant to SDS-PAGE.
Identification of the CK-B Fragments Displaying an Affinity for Morphine
To identify the morphine-binding motifs of CK, six overlapping peptides, namely CK-B 1-75 , CK-B 65-140 , CK-B 127-199 , CK-B 184-258 , CK-B 248-343 and CK-B 286-381 were tested for morphine, M3G, M6G and codeine binding via ELISA (Figure 2A) . Increasing concentrations of opiates (0.1 µM to 324 µM) were added to wells pre-coated with the peptides (0.5 µg). CK-B 1-75 and CK-B 184-258 were able to bind morphine (Figures 2B,C) with a calculated Kd of 12.5 µM and 13.2 µM, respectively. However, ELISA analysis revealed that the six CK-derived peptides have no affinity for M3G, M6G or codeine (Figures 2B,C) . Circular dichroism analysis revealed that in H 2 O, CK-B 1-75 adopts a structure consisting of 3% alpha helix, 15% beta sheets and 82% random coils. Similarly, the calculated secondary structure of CK-B 184-258 is 8% alpha helix, 19% beta sheets and 73% random coils. Focusing on the CK-B 184-258 peptide, we tested the affinity of four smaller overlapping peptides , CK-B 214-238 , CK-B 214-238 ). None of these four peptides displayed an affinity for morphine using an ELISA approach (data not shown).
Taken together, these results indicate that mouse CK-B 1-75 and CK-B 184-258 have a micromolar range affinity restricted to morphine, as observed for the mouse rCK-B.
Characterization of the Effect of Morphine Binding on rCK-B Activity in vitro
Next, we measured the potential impact of morphine binding to CK-B on the formation of ATP from phosphocreatine. Mouse rCK-B (1 µg) was incubated in the presence of increasing concentrations of morphine (0, 0.01, 0.1, 1, 10, 25, 50 and 100 µM; Figure 3A) . The activity of rCK-B was monitored by measuring the production of ATP during 20 min. Morphine (1 µM) significantly decreased the formation of ATP by 27% (36.4 ± 1.8 nmol/min/mg) compared to the control condition (50 ±1.4 nmol/min/mg). Further increasing morphine concentrations dose-dependently inhibited CK-B activity until a maximal level of inhibition was reached (80% decrease in activity for morphine >50 µM). This experiment shows that 1 µM morphine, corresponding to a concentration close to the Kd of CK-B for morphine, significantly decreases CK-B activity in vitro.
Characterization of the Effect of Morphine on CK-B Activity in vivo
In mice, the effect of morphine on CK-B activity in vivo was measured after a single injection of morphine (7.5 mg/kg, i.p.). Endogenous CK-B activity was tested on 75 µg of brain extract, by monitoring ATP production over 10 min. Results indicate that acute morphine treatment induces a statistically significant decrease of CK-B activity by 15.3% (1.60 ± 0.09 µmole/min/mg of total brain protein) compared to saline-treated animals (1.89 ± 0.06 µmole/min/mg of total brain protein; Figure 3B ).
DISCUSSION
The present study reports that recombinant mouse rCK-B displays a micromolar affinity for morphine but not for M3G, M6G or codeine. Two morphine-binding sites were identified, namely peptides CK-B 1-75 and CK-B 184-258 , which displayed a similar micromolar affinity for morphine. In addition, we show that CK-B-morphine complexes are resistant to detergents (SDS), chaotropic agents (urea), reducing agents and heat treatment. Finally, our results show that at a concentration that results in complex formation, morphine significantly decreases the activity of the mouse rCK-B in vitro and endogenous mouse brain CK-B in vivo.
The Morphine-CK-B Complexes
CK-B is the main I2B site for imidazoline and derivatives (such as clonidine, guanfacine. . .; Gentili et al., 2006; Kimura et al., 2009; Li, 2017) . In addition, CK was described to covalently bind dopamine (Van Laar et al., 2009) , which is a morphine precursor in plants and animals (Laux-Biehlmann et al., 2013) , and to form highly stable complexes with ASB9 (Kwon et al., 2010; Balasubramaniam et al., 2015) . However, the potential binding of CK-B to morphine, as well as a potential modulatory role of morphine on CK-B activity, have never been studied. Covalent binding of morphine to proteins has been first proposed by and . This group was able to demonstrate that a single subcutaneous injection of 10 mg/kg of [ 14 C]-morphine-N-methyl led to morphine-related radioactivity lasting in the rat CNS for at least 3 weeks. Later, [C1-3 H]-morphine and [N-14 CH 3 ]-morphine were found to irreversibly bind insoluble tissue components after administration (Mullis et al., 1979; Nagamatsu et al., 1983) . In addition, S-glutathionylmorphine complexes have been characterized (Correia et al., 1984; Kumagai et al., 1990) and are likely formed first by the action of morphine-6-deshydrogenase (EC 1.1.1.218) leading to the formation of morphinone (Endo et al., 2013) , followed by a spontaneous step allowing conjugation to glutathione (GSH) or proteins displaying cysteine residues. Besides, the binding of morphine to 35-50 kDa proteins in mice has also been reported (Nagamatsu et al., 1983; Hasegawa, 1992, 1993) . Morphine binding to these unknown proteins was described as ''covalent'' because morphine-protein complexes were resistant to both methanol precipitation and SDS-PAGE denaturing conditions (Nagamatsu and Hasegawa, 1992) .
In this article, we similarly unveil the formation of mouse rCK-B-morphine complexes that are resistant to SDS-PAGE treatment. Such a strong binding seems incompatible with the micromolar range affinity measured by ELISA. However, ELISA only reflects a biased affinity: (i) resulting from conditions that do not especially promote interactions of morphine with CK-B or its derived fragments; and (ii) dependent on the primary and secondary antibodies. This point is strengthened by the fact that both CK-B 1-75 and CK-B 184-258 display an affinity (µM range) similar to that of the full-length mouse rCK-B. In addition, the control condition performed with a nonspecific morphine-binding protein (i.e., BSA) did not result in any binding and therefore highlights the stringency of our ELISA (Judis, 1977; Leow et al., 1993) . It is likely that morphine-binding sites are present in a well-defined structure of the peptides rather than in unstructured parts. Smaller CK-B 184-258 -derived peptides did not show any affinity for morphine, therefore we could not determine a specific morphine-binding site. This suggests that multiple structural parts all along the sequence of CK-B 184-258 are required for the binding of morphine. The formation of strong morphine-CK-B complexes can be explained by two hypotheses: (i) non-covalent interactions involving ionic, hydrophobic and/or van der Waals interactions lead to a highly stable complex or (ii) a covalent binding of morphine to cysteine residues present in the CK-B occurs. However, our in vitro experimental conditions rule out a possible crosslinking involving cysteine residues (experiments performed in reducing conditions) and the action of morphine-6-deshydrogenase (reaction media do not contain this enzyme). Thus, it is likely that non-covalent complexes are formed with morphine and involve specific interactions as shown for the CK-ASB9 complexes (Balasubramaniam et al., 2015) .
CK-B Activity Modulation by Morphine
As CK-B represents a crucial enzyme that regulates ATP bioavailability in the brain, the ability of morphine to alter CK-B activity may dramatically affect CNS metabolism. Notably, the binding of the irreversible I2B ligand BU99006 (20 µM) to CK-B was shown to decrease the apparent Vmax of CK-B by up to 16% (Kimura et al., 2009 ). However, other I2B ligands (2-BFI, BU224, agmatine) did not affect CK-B activity. In addition, it was shown that a chronic administration of cannabidiol increases CK activity by up to 20% in the rat brain (Valvassori et al., 2013) .
The implication of I2B sites in the modulation of morphine-induced analgesia has been well documented (Sanchez-Blázquez et al., 2000; Gentili et al., 2006; Ciubotariu and Nechifor, 2012; Caprioli et al., 2015) and the involvement of I2B sites in the modulation of morphine withdrawal and tolerance has been reported in rodents (Boronat et al., 1998; Ruiz-Durántez et al., 2003; Miralles et al., 2005) . For example, the I2 ligand agmatine increases morphine-induced analgesia and inhibits tolerance and dependence to opioids (Dardonville et al., 2006) .
In the brain, changes in the expression of energy metabolism enzymes contribute to behavioral abnormalities during chronic morphine treatment (Chen et al., 2007) but can also deeply impact gliotransmission through the modulation of ATP release (Harada et al., 2016) . Accordingly, morphine-binding significantly decreases CK-B enzymatic activity by 27% when morphine is present at a concentration close to the Kd value. In addition, we have shown that in vivo, CK-B activity in brain tissue is decreased by 15 % after injection of an analgesic dose of morphine. Interestingly, our results are in agreement with the effect of morphine on ATP levels in the rat neocortex and thalamus, where respective decreases of 14% and 26% have been observed in vivo (Nasello et al., 1973) .
Our results reveal two potential morphine-CK-B binding sites, namely CK-B 1-75 and CK-B 184-258 . The former is not involved in CK-B activity. Conversely, CK-B 184-258 contains a conserved, negatively charged amino acid cluster, Glu 226 , Glu 227 , Asp 228 (EED) located in the active site of CK isoenzymes (Eder et al., 2000) . This particular motif has been described as essential for CK enzymatic activity. Thus, we can hypothesize that morphine alters CK-B function through binding to the CK-B 184-258 sequence. A limitation of our study is that we only evaluated a fixed time point after euthanizing the animals, and a different pattern of CK-B responses might occur at different time points. Further clarification of the impact of morphine on CK-B function in vivo is needed, e.g., through brain microdialysis and ATP quantification. Another open question is the impact of chronic morphine treatment in patients on CK-B activity, which is likely to differ from our acute morphine-exposure treatment. Indeed, a chronic morphine exposure might inhibit CK-B during a long period leading to important physiological changes and a measurable phenotype.
In vivo Complex Formation
After administration, morphine rapidly reaches the CNS where it binds to mu opioid receptors (MORs) to produce analgesia. Then, morphine is taken up by glial cells including microglial cells and astrocytes through the action of the organic cation transporter OCT1 (Tzvetkov et al., 2013) . After conversion by UDP-glucuronosyl-transferase (UGT) enzymes (King et al., 2000; Weinsanto et al., 2018) , glucuronides are released through the efflux MRP3 transporter (multidrug resistance protein 3; Zelcer et al., 2005) . In this context, it is plausible that after administration and cellular uptake, morphine can form complexes with cytoplasmic CK-B and therefore negatively modulate its activity. Interestingly, injection (i.v., i.p. or s.c.) of an analgesic dose of morphine (10 to 20 mg/kg) to mice results in serum concentrations ranging from 2 µM to 35 µM. Similarly, morphine content in the brain reaches nmol/g of tissue levels (corresponding to a µM range), indicating that our findings are relevant in vivo (Patrick et al., 1975; Vekovischeva et al., 2001; Handal et al., 2002; Xie et al., 2017) .
Endogenous morphine has been detected in numerous cerebral areas and brain cells of different species including the mouse (Laux et al., 2011 Laux-Biehlmann et al., 2013) . Specifically, endogenous morphine is detected in GABA-basket cells, astrocytes and microglial cells (Muller et al., 2008; Laux et al., 2011 Togna et al., 2013) . In addition, an increase of endogenous morphine and M6G blood levels has been linked to stress (Meijerink et al., 1999; Brix-Christensen et al., 2000; Goumon et al., 2000) and pathologies such as sepsis, with concentrations reaching up to 0.25 µM (Glattard et al., 2010; Laux-Biehlmann et al., 2012) . In contrast to opioidergic peptides (e.g., enkephalins), the functional role of endogenous morphine in the CNS remains to be elucidated. Endogenous morphine is found in the cytoplasm of astrocytes expressing both OCT1 (Schreiber et al., 1990) and CK-B (Tachikawa et al., 2004) . Although endogenous morphine concentrations are unlikely to reach 1 µM, uptake by astrocytic processes could theoretically bring endogenous morphine in contact with cytoplasmic CK-B. Whether endogenous morphine-CK-B complexes exist and might influence bioavailability of ATP in astrocytes and impact ATP-mediated gliotransmission through CK-B inhibition remains to be investigated in further studies.
Clinical Relevance of Morphine-CK-B Interactions
The in vitro and in vivo impact of morphine on CK-B activity in the mouse raises the question of a potential relevance of morphine-CK-B interactions in the case of clinical or recreational use of morphine or its derivatives in humans.
First, doses administered to morphine-naive humans are usually two orders of magnitude lower than those needed to elicit analgesia in rodents. Thus, peak morphine blood concentrations (and presumably tissue concentrations) after oral therapeutic dosing typically only reach 100 nM (Klimas and Mikus, 2014) , a concentration far below the 1 µM of morphine needed for CK-B modulation.
However, it is possible that intracellular morphine could reach micromolar concentrations in chronically treated, tolerant patients. Indeed, dose escalation following long-term treatment can lead to patients receiving 500 mg of morphine or more per day. Thus, in the case of chronic use of morphine or codeine, whether in clinical (e.g., cancer patients) or drug abuse settings, morphine concentrations rise to low µM levels in both plasma and brain (Säwe et al., 1983; Frost et al., 2016) . In addition, morphine concentrations in the cerebrospinal fluid (CSF) and brain extracellular fluid (ECF) have been reported to reach nM to µM values in different conditions, including epidural injection during chronic intractable pain due to cancer and codeine overdoses (Coombs et al., 1985; Bouw et al., 2001; Ederoth et al., 2004) .
It is also important to mention the fact that M3G concentrations in these cases are far higher than those of morphine. CK-B is an intracellular protein highly expressed in astrocytes which are known to metabolize morphine into M3G (Suleman et al., 1998; Heurtaux et al., 2006; Sabolovic et al., 2007; Ouzzine et al., 2014) . The active uptake of morphine by astrocytes might allow intracellular morphine to reach µM levels. Unfortunately, intracellular morphine concentrations have never been measured in the human brain, although it has been shown in rodents that morphine preferentially accumulates inside cells, especially astrocytes rather than in the ECF or CSF (Stain-Texier et al., 1999; Ouzzine et al., 2014) .
In conclusion, CK-B/morphine interactions have the potential to be of clinical relevance and this warrants further investigation. While morphine concentrations may not reach sufficient levels to significantly impact CK-B activity in normal dosing regimens, chronic administration and high doses administered to tolerant patients might affect ATP bioavailability in humans.
CONCLUSION
Taken together, our results unveil a strong interaction between CK-B and morphine, occurring in vitro and in vivo. This interaction negatively impacts CK-B activity and thus has the potential to affect energy metabolism and glial transmission. Whether or not morphine is able to bind to and modulate CK-M or mitochondrial CK remains to be studied, but this seems likely given a high sequence homology between these enzymes and CK-B. Additional experiments will allow to further elucidate the binding site of morphine and study, in detail, the consequences of this interaction. The impact of CK-B and its derived peptides on morphine analgesia and metabolism will be investigated in the future. Finally, a detailed study has to focus on endogenous morphine in order to determine its potential implication in energy bioavailability in both physiological and pathological processes. 
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